東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Genetic testing for sale: Implicatio...

Williams-Jones, Bryn.

Linked to FindBook

Google Book

Amazon

博客來

Genetic testing for sale: Implications of commercial BRCA testing in Canada.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Genetic testing for sale: Implications of commercial BRCA testing in Canada./
Author:	Williams-Jones, Bryn.
Description:	182 p.
Notes:	Source: Dissertation Abstracts International, Volume: 63-12, Section: A, page: 4344.
Contained By:	Dissertation Abstracts International63-12A.
Subject:	Philosophy. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=NQ75107
ISBN:	0612751074

Genetic testing for sale: Implications of commercial BRCA testing in Canada.
Williams-Jones, Bryn.

Genetic testing for sale: Implications of commercial BRCA testing in Canada. - 182 p.

Source: Dissertation Abstracts International, Volume: 63-12, Section: A, page: 4344.

Thesis (Ph.D.)--The University of British Columbia (Canada), 2002.

Ongoing research in the fields of genetics and biotechnology hold the promise of improved diagnosis and treatment of genetic diseases, and potentially the development of individually tailored pharmaceuticals and gene therapies. Difficulty, however, arises in determining how these services are to be evaluated and integrated equitably into public health care systems such as Canada's. The current context is one of increasing fiscal restraint on the part of governments, limited financial resources being dedicated to health care, and rising costs for new health care services and technologies. This has led to increasing public debate in the last few years about how to reform public health care, and whether we should prohibit, permit or perhaps even encourage private purchase of health care services.

ISBN: 0612751074Subjects--Topical Terms:

516511
Philosophy.

Genetic testing for sale: Implications of commercial BRCA testing in Canada.
LDR:03245nmm 2200325 4500 001 1840269
005 20050721102952.5
008 130614s2002 eng d
020 $a 0612751074
035 $a (UnM)AAINQ75107
035 $a AAINQ75107
040 $a UnM $c UnM
100 1 $a Williams-Jones, Bryn. $3 1928610
245 1 0 $a Genetic testing for sale: Implications of commercial BRCA testing in Canada.
300 $a 182 p.
500 $a Source: Dissertation Abstracts International, Volume: 63-12, Section: A, page: 4344.
500 $a Adviser: Michael M. Burgess.
502 $a Thesis (Ph.D.)--The University of British Columbia (Canada), 2002.
520 $a Ongoing research in the fields of genetics and biotechnology hold the promise of improved diagnosis and treatment of genetic diseases, and potentially the development of individually tailored pharmaceuticals and gene therapies. Difficulty, however, arises in determining how these services are to be evaluated and integrated equitably into public health care systems such as Canada's. The current context is one of increasing fiscal restraint on the part of governments, limited financial resources being dedicated to health care, and rising costs for new health care services and technologies. This has led to increasing public debate in the last few years about how to reform public health care, and whether we should prohibit, permit or perhaps even encourage private purchase of health care services.
520 $a In Canada, some of these concerns have crystallized around the issue of gene patents and commercial genetic testing, in particular as illustrated by the case of Myriad Genetics' patented BRACAnalysis test for hereditary breast and ovarian cancer. While most Canadians who currently access genetic services do so through the public health care system, for those with the means, private purchase is becoming an option. This situation raises serious concerns---about justice in access to health care; about continued access to safe and reliable genetic testing supported by unbiased patient information; and about the broader effects of commercialization for ongoing research and the Canadian public health care system. Commercial genetic testing presents a challenge to health care professionals, policy analysts, and academics concerned with the social, ethical and policy implications of new genetic technologies. Using the Myriad case as an exemplar, tools from moral philosophy, the social sciences, and health policy and law will be brought to bear on the larger issues of how as a society we should regulate commercial research and product development, and more coherently decide which services to cover under public health insurance and which to leave to private purchase. Generally, the thesis is concerned with the question of "how best to bring capital, morality, and knowledge into a productive and ethical relationship" (Rabinow 1999, 20).
590 $a School code: 2500.
650 4 $a Philosophy. $3 516511
650 4 $a Law. $3 600858
650 4 $a Biology, Genetics. $3 1017730
650 4 $a Biology, Molecular. $3 1017719
650 4 $a Health Sciences, Public Health. $3 1017659
690 $a 0422
690 $a 0398
690 $a 0369
690 $a 0307
690 $a 0573
710 2 0 $a The University of British Columbia (Canada). $3 626643
773 0 $t Dissertation Abstracts International $g 63-12A.
790 1 0 $a Burgess, Michael M., $e advisor
790 $a 2500
791 $a Ph.D.
792 $a 2002
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=NQ75107